We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Medisyn Technologies, a company that has fashioned a rapid drug-design and development
process, has raised $1.5 million in bridge financing as it seeks to accelerate
its own development.
PTC Therapeutics, (PTC), a biopharmaceutical company
focused on the discovery, development and commercialization of small-molecule
drugs targeting post-transcriptional control mechanisms, has announced that
the company has been awarded $1.7 million from Cystic Fibrosis Foundation Therapeutics,
(CFFT), the drug discovery and development affiliate of the Cystic Fibrosis
Foundation.
The FDA's Electronic Submissions Gateway has moved a step closer to reality
as the agency selected the vendors that will build the system, a central collection
portal for electronic submissions from FDA-regulated industries and other government
agencies.
Two drugmakers have sent "Dear Healthcare Professional" letters to
physicians alerting them about the potential for medication mix-ups and adverse
drug interactions involving their products.
Ferring Pharmaceuticals is appealing
a recent court ruling that cut short its patent protection on antidiuretic treatment
DDAVP -- a move that could delay the launch of a generic version of DDAVP by
Barr Laboratories.
Ivax has signed a settlement agreement with rival Alpharma that will enable
it to launch a generic version of Pfizer's Neurontin before Alpharma's 180 days
of marketing exclusivity expires.
Newron Pharmaceuticals SpA, a research and development company focused on novel
CNS therapies, announced the raising of EUR 30 million (fully committed), out
of which EUR 23 million closed.
Ranbaxy Laboratories will set up a majority-owned joint venture in Mexico to
tap the growing demand for generic drugs there. The joint venture with a Mexican
firm will cater to the marketing and distribution demands of the local market.
Quintiles, the North American clinical development subsidiary of Quintiles Transnational,
and the University of North Carolina at Chapel Hill have announced the creation
of a new alliance for clinical research.
Novartis announced that it will buy generic drugmakers Eon Labs of the United
States and Hexal of Germany for $8.3 billion, creating the world's largest generic
drug company.